Precisely tuned inhibition of HIF prolyl hydroxylases is key for cardioprotection after ischemia.

Jatho, Aline; Zieseniss, Anke; Brechtel-Curth, Katja; Yamamoto, Atsushi; Coleman, Mathew L; Leon, Ana M Vergel; Biggs, Daniel; Davies, Ben; Pugh, Chris W; Ratcliffe, Peter J; Katschinski, Dörthe M

CIRCRESAHA.120.318216 (2).pdf (1.32 MB)

Precisely tuned inhibition of HIF prolyl hydroxylases is key for cardioprotection after ischemia.

journal contribution

posted on 2021-04-27, 08:52 authored by Aline Jatho, Anke Zieseniss, Katja Brechtel-Curth, Atsushi Yamamoto, Mathew L Coleman, Ana M Vergel Leon, Daniel Biggs, Ben Davies, Chris W Pugh, Peter J Ratcliffe, Dörthe M Katschinski

No description supplied

Funding

Crick (Grant ID: 10501, Grant title: Ratcliffe FC001501)

History

Publisher DOI

https://doi.org/10.1161/CIRCRESAHA.120.318216

Usage metrics

Keywords

Prolyl Hydroxylase domain enzyme doxycycline heart failure incidence myocardial infarction prolyl hydroxylase Ratcliffe FC001501 1102 Cardiorespiratory Medicine and Haematology 1103 Clinical Sciences Cardiovascular System & Hematology

Licence

CC BY 4.0

Precisely tuned inhibition of HIF prolyl hydroxylases is key for cardioprotection after ischemia.

Funding

Crick (Grant ID: 10501, Grant title: Ratcliffe FC001501)

History

Publisher DOI

Usage metrics

Categories

Keywords

Licence

Exports